Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Resolution of thrombocytopenia with JAK2 mutation in a patient with Gaucher disease.

Amato D, Wang C.

Blood. 2013 Dec 19;122(26):4287-8. doi: 10.1182/blood-2013-08-524447. No abstract available.

2.

Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia.

Grisouard J, Hao-Shen H, Dirnhofer S, Wagner KU, Skoda RC.

Haematologica. 2014 Apr;99(4):e52-4. doi: 10.3324/haematol.2013.100016. Epub 2014 Feb 7. No abstract available.

3.

Positive JAK2-V617F leading to diagnosis of Gaucher's disease.

Appiah-Cubi S, Wilkins BS, Harrison C.

J Clin Pathol. 2012 Aug;65(8):764-5. doi: 10.1136/jclinpath-2012-200705. Epub 2012 Mar 29. No abstract available.

PMID:
22461650
4.

JAK2V617F mutation and myeloproliferative malignancy in a patient with Type 1 Gaucher disease.

Webb BD, Weinreb NJ, Botti AC, Kirmse BM, Balwani M.

Blood Cells Mol Dis. 2011 Jan 15;46(1):103-4. doi: 10.1016/j.bcmd.2010.09.007. Epub 2010 Oct 23. No abstract available.

PMID:
20971662
5.

JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.

Kreft A, Kindler T, Springer E, Kirkpatrick CJ.

Virchows Arch. 2011 Nov;459(5):521-7. doi: 10.1007/s00428-011-1154-2. Epub 2011 Oct 18.

PMID:
22006129
6.

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.

Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T.

Haematologica. 2007 Jan;92(1):135-6.

7.

Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.

Lakey MA, Pardanani A, Hoyer JD, Nguyen PL, Lasho TL, Tefferi A, Hanson CA.

Am J Clin Pathol. 2010 Jun;133(6):942-8. doi: 10.1309/AJCP3Z2AKUWRGTNM.

8.
9.

Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.

Wang YL, Lee JW, Kui JS, Chadburn A, Cross NC, Knowles DM, Coleman M.

Acta Haematol. 2007;118(4):209-14. Epub 2007 Nov 21.

PMID:
18032883
10.

Novel G377S (c.1246G>T) mutation associated with Gaucher disease type 1.

Zhou Y, Kraemer RR, Peker D, Wakefield DN, de Idiaquez Bakula DA.

Am J Hematol. 2013 Oct;88(10):922-3. doi: 10.1002/ajh.23537. Epub 2013 Aug 1. No abstract available.

11.

Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.

Lapecorella M, Tabilio A, Lucchesi A, Napolitano M, Colagrande M, Di Ianni M, Mariani G.

Blood Coagul Fibrinolysis. 2008 Jul;19(5):453-7. doi: 10.1097/MBC.0b013e3283079e46.

PMID:
18600099
12.

Acute neuronopathic (infantile) and chronic nonneuronopathic (adult) Gaucher disease in full siblings.

Wenger DA, Roth S, Sattler M.

J Pediatr. 1982 Feb;100(2):252-4. No abstract available.

PMID:
7057336
13.

Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome.

Letestu R, Vitrat N, Massé A, Le Couedic JP, Lazar V, Rameau P, Wendling F, Vuillier J, Boutard P, Plouvier E, Plasse M, Favier R, Vainchenker W, Debili N.

Blood. 2000 Mar 1;95(5):1633-41.

14.

Intriguing outcome of JAK2V617F mutation seen in a patient with MYH9-related hereditary macrothrombocytopenia.

Fabris F, Scandellari R, Vettore S, Scapin M, Bizzaro N, Randi ML.

Thromb Haemost. 2010 Oct;104(4):858-9. doi: 10.1160/TH10-01-0041. Epub 2010 Aug 5. No abstract available.

PMID:
20694274
15.

JAK2 mutations and coronary ischemia.

Lata K, Madiraju N, Levitt L.

N Engl J Med. 2010 Jul 22;363(4):396-7. doi: 10.1056/NEJMc1003478. No abstract available.

16.

Adult Gaucher disease in southern Tunisia: report of three cases.

Ben Rhouma F, Kallel F, Kefi R, Cherif W, Nagara M, Azaiez H, Jedidi I, Elloumi M, Abdelhak S, Mseddi S.

Diagn Pathol. 2012 Jan 10;7:4. doi: 10.1186/1746-1596-7-4.

17.

The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.

Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B, Kiladjian JJ, Varkonyi J, Antunovic P, Westwood NB, Arno MJ, Mohamedali A, Gaken J, Kontou T, Czepulkowski BH, Twine NA, Tamaska J, Csomer J, Benedek S, Gattermann N, Zipperer E, Giagounidis A, Garcia-Casado Z, Sanz G, Mufti GJ.

Leukemia. 2006 Jul;20(7):1319-21. Epub 2006 Apr 13. No abstract available.

PMID:
16617322
18.

Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation.

Lu CM, Zhou L, Wang E, Feng S, Sebastian S, Behler C.

Leuk Lymphoma. 2011 Dec;52(12):2405-7. doi: 10.3109/10428194.2011.597907. Epub 2011 Aug 1. No abstract available.

PMID:
21806348
19.

High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.

De Stefano V, Fiorini A, Rossi E, Za T, Chiusolo P, Sica S, Leone G.

Hepatology. 2007 Mar;45(3):831-2; author reply 832-3. No abstract available.

PMID:
17326212
20.

An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.

Zhang SJ, Li JY.

Chin Med J (Engl). 2008 Sep 20;121(18):1838-42. No abstract available.

PMID:
19080367
Items per page

Supplemental Content

Write to the Help Desk